Hofmeister Robert 4
4 · TCR2 THERAPEUTICS INC. · Filed Nov 13, 2020
Insider Transaction Report
Form 4
Hofmeister Robert
Chief Scientific Officer
Transactions
- Sale
Common Stock
2020-11-12$25.10/sh−10,002$251,050→ 38,850 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-11-12−9,998→ 12,348 totalExercise: $0.74From: 2018-12-07Exp: 2027-12-07→ Common Stock (9,998 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-11-12−10,002→ 25,730 totalExercise: $0.74From: 2017-12-13Exp: 2026-12-13→ Common Stock (10,002 underlying) - Exercise/Conversion
Common Stock
2020-11-12$0.74/sh+9,998$7,399→ 48,848 total - Sale
Common Stock
2020-11-12$25.10/sh−9,998$250,950→ 38,850 total - Exercise/Conversion
Common Stock
2020-11-12$0.74/sh+10,002$7,401→ 48,852 total
Footnotes (3)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]25% of this option vested and become exercisable on December 7, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
- [F3]25% of this option vested and become exercisable on December 13, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.